Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges
Open Access
- 25 May 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1211388
- https://doi.org/10.3389/fimmu.2023.1211388
Abstract
Controlled Human Infection Models (CHIMs) involve deliberately exposing healthy human volunteers to a known pathogen, to allow the detailed study of disease processes and evaluate methods of treatment and prevention, including next generation vaccines. CHIMs are in development for both tuberculosis (TB) and Covid-19, but challenges remain in their ongoing optimisation and refinement. It would be unethical to deliberately infect humans with virulent Mycobacteria tuberculosis (M.tb), however surrogate models involving other mycobacteria, M.tb Purified Protein Derivative or genetically modified forms of M.tb either exist or are under development. These utilise varying routes of administration, including via aerosol, per bronchoscope or intradermal injection, each with their own advantages and disadvantages. Intranasal CHIMs with SARS-CoV-2 were developed against the backdrop of the evolving Covid-19 pandemic and are currently being utilised to both assess viral kinetics, interrogate the local and systemic immunological responses post exposure, and identify immune correlates of protection. In future it is hoped they can be used to assess new treatments and vaccines. The changing face of the pandemic, including the emergence of new virus variants and increasing levels of vaccination and natural immunity within populations, has provided a unique and complex environment within which to develop a SARS-CoV-2 CHIM. This article will discuss current progress and potential future developments in CHIMs for these two globally significant pathogens.This publication has 71 references indexed in Scilit:
- Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in CombinationThe Journal of Infectious Diseases, 2013
- A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-GuérinThe Journal of Infectious Diseases, 2012
- Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin testEuropean Journal of Immunology, 2011
- Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine EfficacyPLOS ONE, 2011
- An investigation of clinical and immunological events following repeated aerodigestive tract challenge infections with live Mycobacterium bovis Bacille Calmette GuérinVaccine, 2010
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of ProtectionThe Journal of Infectious Diseases, 2009
- The Immune Response to BCG Vaccination of NewbornsAnnals of the New York Academy of Sciences, 2005
- Resident Th1-Like Effector Memory Cells in Pulmonary Recall Responses toMycobacterium tuberculosisAmerican Journal of Respiratory Cell and Molecular Biology, 2005
- Recruitment of Antigen-Specific Th1-Like Responses to the Human Lung following Bronchoscopic Segmental Challenge with Purified Protein Derivative of Mycobacterium tuberculosisAmerican Journal of Respiratory Cell and Molecular Biology, 2003
- ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTIONThe Lancet, 1984